Markets

BeOne Medicines Announces Its Data From Phase 3 HERIZON-GEA-01 Study Confirms Benefits Of TEVIMBRA + ZIIHERA To Treat Patients With HER2-Positive Locally Advanced Or Metastatic Gastroesophageal Adenocarcinoma

Oct 23, 2026 · 10:18 AM ET· updated 1h ago

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3

Why It Matters

BeOne's cancer medicine combo passed its big final test. The drug worked well enough that doctors can now decide if patients should use it.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ONC374.42

-7.85 (-2.05%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.